Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

In 2013 Staffan Strömberg was appointed CEO of Infant Bacterial Therapeutics AB (publ) (STO:IBT B). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. After that, we will consider the growth in the business. And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. This process should give us an idea about how appropriately the CEO is paid.

Check out our latest analysis for Infant Bacterial Therapeutics

How Does Staffan Strömberg's Compensation Compare With Similar Sized Companies?

Our data indicates that Infant Bacterial Therapeutics AB (publ) is worth kr2.6b, and total annual CEO compensation is kr3.1m. (This number is for the twelve months until December 2017). While this analysis focuses on total compensation, it's worth noting the salary is lower, valued at kr1.5m. As part of our analysis we looked at companies in the same jurisdiction, with market capitalizations of kr940m to kr3.8b. The median total CEO compensation was kr3.1m.

So Staffan Strömberg is paid around the average of the companies we looked at. While this data point isn't particularly informative alone, it gains more meaning when considered with business performance.

You can see a visual representation of the CEO compensation at Infant Bacterial Therapeutics, below.

Is Infant Bacterial Therapeutics AB (publ) Growing?

On average over the last three years, Infant Bacterial Therapeutics AB (publ) has grown earnings per share (EPS) by 7.0% each year (using a line of best fit). In the last year, its revenue is down -100%.

I generally like to see a little revenue growth, but it is good to see EPS growth. These two metric are moving in different directions, so while it's hard to be confident judging performance, we think the stock is worth watching. Shareholders might be interested in this free visualization of analyst forecasts.

Has Infant Bacterial Therapeutics AB (publ) Been A Good Investment?

I think that the total shareholder return of 402%, over three years, would leave most Infant Bacterial Therapeutics AB (publ) shareholders smiling. So they may not be at all concerned if the CEO were to be paid more than is normal for companies around the same size.

In Summary...

Remuneration for Staffan Strömberg is close enough to the median pay for a CEO of a similar sized company .